Bioverativ inks $100M gene therapy deal with Oxford BioMedica – Endpoints News
Endpoints News |
Bioverativ inks $100M gene therapy deal with Oxford BioMedica
Endpoints News But thanks to Spark Therapeutics, which got the FDA OK to treat blindness with gene therapy drug Luxturna late last year, the entire field is now coming of age. And now Oxford BioMedica is cashing in. The new deal will get Bioverativ access to Oxford's … Oxford BioMedica wins second $100 million gene therapy contract Oxford BioMedica, Bioverativ to Develop Lentiviral Vectors for Hemophilia Gene Therapy Oxford BioMedica share price rises on $100m gene therapy deal with Bioverativ |
